Drug Target Review

DECEMBER 28, 2023

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. This allows the cancer to evolve and develop resistance to the therapy.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

DNA 52

DNA Bioinformatics Production Engineering 52

Codon

MAY 15, 2023

3/ Prime Editing Spree Prime editors can change DNA in ways that Cas9 — and even base editors — cannot. Known as a "search-and-replace" gene-editing tool, prime editors can delete or replace DNA up to 10,000 bases in length, or substitute one base for another. Read more in Cell. ( #1 , #2 ) (Video credit: Gong Y.

DNA 52

DNA Bioinformatics Engineering Virus 52

Codon

MAY 15, 2023

3/ Prime Editing Spree Prime editors can change DNA in ways that Cas9 — and even base editors — cannot. Known as a "search-and-replace" gene-editing tool, prime editors can delete or replace DNA up to 10,000 bases in length, or substitute one base for another. Read more in Cell. ( #1 , #2 ) (Video credit: Gong Y.

DNA 52

DNA Bioinformatics Engineering Virus 52

Vial

DECEMBER 5, 2023

In 2017, the Food & Drug Administration (FDA) approved the first gene therapy for cancer and for inherited diseases, the first multiplex NGS panel for companion diagnostics (CDx), and the first drug targeting a genetic signature though not a disease. Fountzilas et al. Satam et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Anticancer Fund

MARCH 24, 2023

Using patient-derived xenograft models the authors then show that the addition of celecoxib to standard of care targeted therapies leads to improved survival and durable responses. COX2 inhibition, using celecoxib, reduces PGE2 and averts the resistance to BRAF treatment. These results clearly warrant clinical investigation.

Drugs 52

Drugs DNA Trials Treatment 52

Broad Institute

AUGUST 4, 2022

To build the CLL map, the team analyzed variations in genetic sequences, gene expression patterns, and chemical modifications to DNA — or genomic, transcriptomic, and epigenomic data — from 1,148 patients.

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52